Navigation Links
Promise for Soya Allergy Sufferers

Two Chinese soybean lines that grow without the primary protein linked to soy allergies in children and adults have been isolated by scientists//.

The two lines already are adapted to Illinois-like conditions and will be given away to breeders seeking to produce new varieties of allergy-free soybeans without genetic engineering.

Crop scientists at the University of Illinois at Urbana-Champaign and the USDA-Agricultural Research Service's Donald Danforth Plant Science Center in St. Louis screened more than 16,000 soybean lines kept in the USDA's National Soybean Germplasm Collection. The findings will appear later this year in the journal Crop Science.

The two soybean lines (PI 567476 and PI 603570A) contain virtually identical genetic mutations that do not contain the leading allergy-causing P34 protein, which consists of 379 amino acids, said Theodore Hymowitz, emeritus professor of plant genetics in the crop sciences department at the U. of I.

‘We are releasing this information with no patents so that companies and breeders involved with soybeans can incorporate these two lines as quickly as possible,’ Hymowitz said. Companies in Japan, Canada and across the United States have been following the research effort, he added.

The research, which was funded primarily by the Illinois-Missouri Biotechnology Alliance, went through two stages.

First, using a specially developed immunochemistry approach, Hymowitz's post-doctoral assistant Leina M. Joseph examined 100 lines of soybeans per day for nine months from the UI-based collection. Seeds were crushed, treated and placed on a membrane for screening. A second screening using stronger antibodies and protein gels was done to confirm the absence of P34 in the two domestic lines, Joseph said.

After the two lines were isolated, seeds were sent to the Danforth Center for additional molecular analysis to determine why P34 was absent. Six ident ical genetic mutations were found in each, indicating the two lines may be related, Hymowitz said.

‘The lack of the protein was confirmed by more-detailed two-dimensional protein assays,’ said Eliot M. Herman, a lead scientist at Danforth who probed the seeds with post-doctoral researcher Monica A. Schmidt. ‘We then isolated the gene responsible for the lesion, and we found there was a single significant change in the gene's sequence that likely produced a protein which could not be made as a stable product.’

Herman discovered P34 in the early 1990s and in 2003 had successfully used a gene-silencing technique to create a soybean line in which P34 was ‘knocked out.’ However, because of public resistance to genetically modified products researchers have been seeking a more traditional approach. Because the newly identified lines occur naturally, they can be successfully crossed into other soybean lines ‘without any biotechnology-derived component,’ the researchers noted.

‘Soybeans are slowly but surely increasingly being used in the foods we eat, and with that we are noticing an increase in the number of children and adults that have allergies to soybeans,’ Hymowitz said.

Currently, 6 percent to 8 percent of children are allergic to soy-based products, including infant formulas, while 2 percent of adults have had allergic reactions, which range from harmless skin reactions and gastrointestinal irritation to more serious facial swelling, shortness of breath, difficulty swallowing and fainting.

Avoiding soy products is becoming more difficult because of soy's use as fillers and components of many menu items. While people can read labels before preparing meals at home, avoiding soy at restaurants isn't as easy, Hymowitz said.

'"/>




Related medicine news :

1. New Prostate Cancer Vaccine Shows Promise
2. Ebola Treatment Shows Promise
3. Stem Cells Found To Offer Promise For Hair Growth
4. Promised Drug Doesnt Help Acute Heart Failure
5. Marijuana-Derived Drug Promises Hope In Treating Bladder Infection
6. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
7. New Pancreatic Cancer Vaccine Holds Promise
8. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
9. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection
10. Maternal Vitamin D Supplementation Promises Healthy Bones In Child
11. Cervical Cancer Vaccine Show Promise In Prevention
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... 10, 2016 , ... As part of its ongoing series of aquatic therapy ... webinar features a dynamic expert and thoughtful presentation to give attendees a better sense ... Both events are free to attend, but registration is required. , Rehabilitation ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency ... to assist the local community. Pledging to select a new beneficiary every 60 ... the area. Their goal is to bring community awareness to important local causes ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... three leading bottled water brand owners that topped the list as a result of ... optimize conversion. The premier brand was Tibet 5100, a top notch water company that ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Dr. Jessica ... the practice is now accepting new dental patients and families in the North Metro ... dental care services from cleanings to cosmetic dentistry, and all in the most relaxing ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, LLC, ... new approaches to the treatment of lupus and ... a multiple ascending dose study in patients with ... RSLV-132. --> --> ... multiple ascending dose study of RSLV-132 in 32 ...
(Date:2/10/2016)... Urologix, the market leader for in-office minimally ... Hyperplasia (BPH), announces new private ownership and is operating ... device industry veteran of more than 20 years, has ... Plymouth, Minn. The company,s ... Prostiva® RF Therapy, will continue to be broadly available ...
(Date:2/10/2016)... -- Astellas Pharma Inc. (TSE: 4503, President and CEO: ... successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition ... and outstanding shares of common stock of Ocata Therapeutics, ... , "Ocata") for a price of US$8.50 per share ... commenced the Tender Offer on November 19, 2015, U.S. ...
Breaking Medicine Technology: